GRAIL
154.08USD+7.55%Share
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
What's happening?
GRAL is outpacing Healthcare this month: +91.8% against +3.8% for the average Healthcare stock.
Above its 200-day average since 7 Aug · 24 of 34 Healthcare stocks are trending up.
- 1D
- +7.55%
- 7D
- +16.17%
- 1M
- +91.78%
- 3M
- +123.47%
- 6M
- +197.80%
- YTD
- +80.02%
What is the market expecting?
No forward P/E, as a loss is expected; analysts' mean target sits 27.1% below the price.
Not ranked on value: this stock carries too few of the multiples to score against its sector.
Is the business delivering?
Revenue +25.7% on a year ago; met or beat the estimate in 4 of the last 4 quarters.
Earnings by quarter
Latest quarter -110M · -17.1M on the quarter before · +3.74M on a year earlier
- -126MNov24—
- -97.1MFeb25+28.6M
- -106MMay25-9.15M
- -114MAug25-7.77M
- -89.0MNov25+25.0M
- -99.2MFeb26-10.2M
- -93.2MMay26+5.99M
- -110MAug26-17.1M
Net income from the income statement, in USD, by the month it was reported.
How does it compare?
Value rankingGRAL is not ranked on value, so there are no nearest stocks to set it against.
What happens next?
Reports next on 11 Nov, in 37 days.
Fundamentals
On the shortlist
GRAL isn't in any strategy's Top Matches or Close Matches today.
In the briefing
Briefing for 5 OctThe briefing has not named GRAL.
Shortlist history
GRAL has not made the shortlist since the ledger opened.
Keep researching
Where next from GRAL
Daily market updates
Get the daily brief
Get an interesting stock pick, updates on the AI sector, information on the biggest movers of the day, and more, in the Monday to Saturday email.